VivaDiag ™ SARS-Cov-2 Ag Rapid Test
Both tests are designed to detect the presence of SARS-CoV-2 viral antigens in nasal, nasopharyngeal, or oropharyngeal swab samples from patients with suspected COVID-19. They are intended to be used by healthcare professionals for qualitative screening. Using lateral flow-based technology, the VivaDiag ™ SARS-CoV-2 Ag Rapid Test is easy to use and can generate results in 15 minutes, without the need for any other reading instruments. The rapid antigen test is extremely useful for places like the airport, the train station, and the convention center.
The VivaDiag ™ SARS-Cov-2 Ag FIA Test with the POCT VivaDiag ™ Analyzer employs our advanced fluorescent immunoassay platform technology. Its capacity for high analytical precision and high throughput (up to 120 tests per hour) makes it an indispensable tool for the screening, diagnosis, and containment of COVID-19. Neither of the above two products is available for sale in the US yet, although VivaChek is seeking emergency use authorization (US) from the USFDA.
Unfortunately, anyone can see the end of the global pandemic and with the upcoming regular flu season, the mission of fighting COVID-19 seems even more difficult. VivaChek is proud to invest all of our knowledge and resources to develop the VivaDiag ™ SARS-CoV-2 FIA / Flu A / Flu B Ag Combination Test, which will be released in the coming weeks. It can be used for the simultaneous detection and differentiation of SARS-CoV-2, influenza A and influenza B antigens in samples from individuals suspected of respiratory viral infections. The test will serve as a powerful weapon for healthcare professionals to contain the COVID-19 pandemic.
